198 related articles for article (PubMed ID: 10627771)
1. The use of gonadotrophin-releasing hormone antagonists in polycystic ovarian disease.
Lubin V; Charbonnel B; Bouchard P
Baillieres Clin Obstet Gynaecol; 1998 Dec; 12(4):607-18. PubMed ID: 10627771
[TBL] [Abstract][Full Text] [Related]
2. Gonadotropin-releasing hormone (GnRH) analog suppression renders polycystic ovarian disease patients more susceptible to ovulation induction with pulsatile GnRH.
Filicori M; Campaniello E; Michelacci L; Pareschi A; Ferrari P; Bolelli G; Flamigni C
J Clin Endocrinol Metab; 1988 Feb; 66(2):327-33. PubMed ID: 3123511
[TBL] [Abstract][Full Text] [Related]
3. The combination of gonadotrophin-releasing hormone (GnRH) antagonist and pulsatile GnRH normalizes luteinizing hormone secretion in polycystic ovarian disease but fails to induce follicular maturation.
Dubourdieu S; Le Nestour E; Spitz IM; Charbonnel B; Bouchard P
Hum Reprod; 1993 Dec; 8(12):2056-60. PubMed ID: 8150903
[TBL] [Abstract][Full Text] [Related]
4. LH suppression following different low doses of the GnRH antagonist ganirelix in polycystic ovary syndrome.
Hohmann FP; Laven JS; Mulders AG; Oberyé JJ; Mannaerts BM; de Jong FH; Fauser BC
J Endocrinol Invest; 2005 Dec; 28(11):990-7. PubMed ID: 16483177
[TBL] [Abstract][Full Text] [Related]
5. The abnormal response of polycystic ovarian disease patients to exogenous pulsatile gonadotropin-releasing hormone: characterization and management.
Filicori M; Flamigni C; Campaniello E; Valdiserri A; Ferrari P; Meriggiola MC; Michelacci L; Pareschi A
J Clin Endocrinol Metab; 1989 Oct; 69(4):825-31. PubMed ID: 2506216
[TBL] [Abstract][Full Text] [Related]
6. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
7. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
Vuong TN; Phung HT; Ho MT
Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
[TBL] [Abstract][Full Text] [Related]
8. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
Bahçeci M; Ulug U; Ben-Shlomo I; Erden HF; Akman MA
J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
[TBL] [Abstract][Full Text] [Related]
9. The use of a combined regimen of GnRH agonist plus a low-dose oral contraceptive improves the spontaneous pulsatile LH secretory characteristics in patients with polycycstic ovary disease after discontinuation of treatment.
Genazzani AD; Battaglia C; Gamba O; Petraglia F; Malavasi B; Genazzani AR
J Assist Reprod Genet; 2000 May; 17(5):269-75. PubMed ID: 10976414
[TBL] [Abstract][Full Text] [Related]
10. What is the best treatment for women with polycystic ovarian syndrome and high LH/FSH ratio? A comparison among in vitro fertilization with GnRH agonist, GnRH antagonist and in vitro maturation.
Ganor-Paz Y; Friedler-Mashiach Y; Ghetler Y; Hershko-Klement A; Berkovitz A; Gonen O; Shulman A; Wiser A
J Endocrinol Invest; 2016 Jul; 39(7):799-803. PubMed ID: 26797707
[TBL] [Abstract][Full Text] [Related]
11. Effect of gonadotrophin-releasing hormone (GnRH) antagonist during the LH surge in normal women and during controlled ovarian hyperstimulation.
Christin-Maitre S; Olivennes F; Dubourdieu S; Chabbert-Buffet N; Charbonnel B; Frydman R; Bouchard P
Clin Endocrinol (Oxf); 2000 Jun; 52(6):721-6. PubMed ID: 10848876
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the effects of ovarian cauterization and gonadotropin-releasing hormone agonist and oral contraceptive therapy combination on endocrine changes in women with polycystic ovary disease.
Taskin O; Yalcinoglu AI; Kafkasli A; Burak F; Ozekici U
Fertil Steril; 1996 Jun; 65(6):1115-8. PubMed ID: 8641482
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous administration of pulsatile gonadotropin-releasing hormone decreases serum follicle-stimulating hormone and luteinizing hormone levels in women with polycystic ovary syndrome: a preliminary study.
Graña-Barcia M; Liz-Lestón J; Lado-Abeal J
Fertil Steril; 2005 May; 83(5):1466-72. PubMed ID: 15866586
[TBL] [Abstract][Full Text] [Related]
14. Use of a gonadotropin-releasing hormone antagonist as a physiologic probe in polycystic ovary syndrome: assessment of neuroendocrine and androgen dynamics.
Hayes FJ; Taylor AE; Martin KA; Hall JE
J Clin Endocrinol Metab; 1998 Jul; 83(7):2343-9. PubMed ID: 9661606
[TBL] [Abstract][Full Text] [Related]
15. Endocrine dynamics during pulsatile GnRH administration in patients with hypothalamic amenorrhea and polycystic ovarian disease.
Rossmanith WG; Wirth U; Benz R; Wolf AS
Gynecol Endocrinol; 1989; 3(1):21-34. PubMed ID: 2658471
[TBL] [Abstract][Full Text] [Related]
16. Ovarian stimulation by concomitant administration of cetrorelix acetate and HMG following Diane-35 pre-treatment for patients with polycystic ovary syndrome: a prospective randomized study.
Hwang JL; Seow KM; Lin YH; Huang LW; Hsieh BC; Tsai YL; Wu GJ; Huang SC; Chen CY; Chen PH; Tzeng CR
Hum Reprod; 2004 Sep; 19(9):1993-2000. PubMed ID: 15284212
[TBL] [Abstract][Full Text] [Related]
17. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone effect on pulsatile GnRH therapy for ovulation induction in polycystic ovary syndrome: a pilot prospective study.
Fulghesu AM; Ciampelli M; Belosi C; Apa R; Guido M; Caruso A; Mancuso S; Lanzone A
J Endocrinol Invest; 2001; 24(7):483-90. PubMed ID: 11508781
[TBL] [Abstract][Full Text] [Related]
19. Recovery of hormone secretion after chronic gonadotropin-releasing hormone agonist administration in women with polycystic ovarian disease.
de Ziegler D; Steingold K; Cedars M; Lu JK; Meldrum DR; Judd HL; Chang RJ
J Clin Endocrinol Metab; 1989 Jun; 68(6):1111-7. PubMed ID: 2524501
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled study comparing the endocrine effects of pulsatile intravenous gonadotropin-releasing hormone after gonadotropin-releasing hormone agonist pretreatment versus clomiphene citrate in patients with polycystic ovary syndrome.
Timmerman-van Kessel EC; Cikot RJ; Dargel-Donkers EJ; Zwertbroek W; van Dop PA; Schoot DC
Fertil Steril; 2000 Jun; 73(6):1145-8. PubMed ID: 10856472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
